Trial Profile

Prospective Noninterventional Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Tumours (GEP-NETs) in Routine Clinical Practice

Status: Withdrawn prior to enrolment

Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lanreotide (Primary)
Indications Gastro-enteropancreatic neuroendocrine tumour; Gastrointestinal cancer; Pancreatic cancer
Focus Therapeutic Use
Acronyms NETways
Sponsors Ipsen

02 Aug 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
24 Jul 2019 Planned initiation date changed from 1 Jul 2019 to 1 Aug 2019.
26 Jun 2019 Planned initiation date changed from 1 Jun 2019 to 1 Jul 2019.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com